[68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?
Abstract Background The aim of the current study was to assess whether and to what extent monitoring response to treatment using prostate-specific membrane antigen (PSMA)-based positron-emitting tomography/computerized tomography (PET/CT) studies contribute clinically relevant data to routine clinic...
Main Authors: | Jonathan Kuten, David Sarid, Ofer Yossepowitch, Nicola J. Mabjeesh, Einat Even-Sapir |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2019-08-01
|
Series: | EJNMMI Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13550-019-0554-1 |
Similar Items
-
68Ga-PSMA-11 PET/CT Follow-Up of Patients with Prostate Cancer with Bone Metastases Who Had Reduced Bone Density after Androgen Deprivation Therapy
by: Mikhail Kesler, et al.
Published: (2021-02-01) -
The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0
by: Jonathan Kuten, et al.
Published: (2021-01-01) -
Lesion-to-background ratio threshold value of SUVmax of simultaneous [68Ga]Ga-PSMA-11 PET/MRI imaging in patients with prostate cancer
by: Jing Zhao, et al.
Published: (2020-12-01) -
68Ga-PSMA PET/CT in prostate cancer patients – patterns of disease, benign findings and pitfalls
by: Zohar Keidar, et al.
Published: (2018-11-01) -
[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2021-07-01)